Left Ventricular Assist Device is a Viable Therapy in End Stage Hypertrophic Cardiomyopathy

Authors

Mirnela Byku, Washington University in St. LouisFollow
Michael Nassif, Washington University in St LouisFollow
Eric Novak, Washington University in St LouisFollow
Akinobu Itoh, Washington University in St LouisFollow
Greg Ewald, Washington University in St LouisFollow
Shane J. Larue, Washington University in St LouisFollow

Peer Reviewed

1

Publication Date

7-4-2017

Document Type

Original Research

Abstract

Left Ventricular Assist Device (LVAD) therapy use is increasing rapidly in advanced heart failure (HF). Little data exists on the application of this therapy in patients with advanced HF due to Hypertrophic Cardiomyopathy (HCM). Altered ventricular geometry, thickened septum and reduced LV end-diastolic diameter (LVEDD) in HCM may lead to increased suction events, arrhythmias and inflow cannula malfunction.

We hypothesized that patients with end stage HCM benefit from LVAD therapy and have a similar rate of complications to those with ischemic or dilated CM.

Between 2009 and 2014, 5 patients with end stage HCM (HCM and EF

We conclude that select patients with end stage HCM may benefit from LVAD therapy with a similar rate of complications compared to traditional candidates. Additional study is warranted to further evaluate durable mechanical support in this population.

DOI

https://doi.org/10.13023/VAD.2017.08

Creative Commons License

This work is licensed under a Creative Commons Attribution-Noncommercial 4.0 License

Recommended Citation

Byku, Mirnela; Nassif, Michael; Novak, Eric; Itoh, Akinobu; Ewald, Greg; and Larue, Shane J. (2017) "Left Ventricular Assist Device is a Viable Therapy in End Stage Hypertrophic Cardiomyopathy," The VAD Journal: Vol. 3, Article 8.
DOI: https://doi.org/10.13023/VAD.2017.08
Available at: https://uknowledge.uky.edu/vad/vol3/iss1/8